Table 2.
Eraser | Role in cancer | Type | Target ncRNAs | Mechanism |
---|---|---|---|---|
FTO | Oncogene | ESCC | LNC0002299 | Stability |
CC | LncHOXC13-AS100 | Stability | ||
ALKBH5 | Oncogene | OS | LncPVT1104 | Stability |
GBM | LncNEAT1103 | Stability | ||
LSCC | LncKCNQ1OT1117 | Stability | ||
DLBCL | LncTRERNA1111 | Scaffold | ||
CRC | circ3823102 | Stability | ||
HCC | circCPSF6110 | Stability | ||
NSCLC | miR-21–5p112 | Silencing potency | ||
GC | LncNEAT1107 | N/A | ||
CRC | LncNEAT1109 | N/A | ||
LUAD | LncRMRP108 | N/A | ||
Tumor suppressor | ESCC | LNC00278106 | Translation | |
Tumor suppressor | PAC | LncKCNK15-AS1105 | N/A |
ESCC esophageal squamous cell carcinoma, CC cervical cancer, OS osteosarcoma, GBM glioblastoma multiforme, LSCC laryngeal squamous cell carcinoma, DLBCL diffuse large B-cell lymphoma, CRC colorectal cancer, HCC hepatocellular carcinoma, NSCLC non-small cell lung cancer, GC gastric cancer, LUAD lung adenocarcinoma, PAC pancreatic cancer.